HK1218251A1 - 用拉喹莫德治疗多发性硬化症 - Google Patents

用拉喹莫德治疗多发性硬化症 Download PDF

Info

Publication number
HK1218251A1
HK1218251A1 HK16106220.1A HK16106220A HK1218251A1 HK 1218251 A1 HK1218251 A1 HK 1218251A1 HK 16106220 A HK16106220 A HK 16106220A HK 1218251 A1 HK1218251 A1 HK 1218251A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
multiple sclerosis
human subject
treating
treatment
Prior art date
Application number
HK16106220.1A
Other languages
English (en)
Chinese (zh)
Inventor
Tarcic Nora
Bar-Zohar Dan
Hayardeny Liat
Gilgun Sherki Yossi
Gorfine Tali
Knappertz Volker
Sorani Ella
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1218251A1 publication Critical patent/HK1218251A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
HK16106220.1A 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症 HK1218251A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US61/765,394 2013-02-15
US201361911106P 2013-12-03 2013-12-03
US61/911,106 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
HK1218251A1 true HK1218251A1 (zh) 2017-02-10

Family

ID=51351655

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16106269.3A HK1218254A1 (zh) 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症
HK16106220.1A HK1218251A1 (zh) 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16106269.3A HK1218254A1 (zh) 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症

Country Status (18)

Country Link
US (2) US20140235670A1 (enExample)
EP (1) EP2956137A4 (enExample)
JP (1) JP2016510343A (enExample)
KR (1) KR20150119227A (enExample)
CN (1) CN105163737A (enExample)
AU (1) AU2014216199A1 (enExample)
BR (1) BR112015019564A2 (enExample)
CA (1) CA2900503A1 (enExample)
CL (1) CL2015002181A1 (enExample)
EA (1) EA201591507A1 (enExample)
HK (2) HK1218254A1 (enExample)
IL (1) IL240014A0 (enExample)
MX (1) MX2015010296A (enExample)
PE (1) PE20151526A1 (enExample)
SG (1) SG11201505818WA (enExample)
TW (1) TW201442709A (enExample)
UY (1) UY35328A (enExample)
WO (1) WO2014127139A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
AU2015332037A1 (en) * 2014-10-16 2017-04-27 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
LT3506921T (lt) 2016-08-31 2023-08-10 Mapi Pharma Ltd Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
EP4178675A4 (en) * 2020-07-09 2024-08-07 Oklahoma Medical Research Foundation BIOMARKERS FOR THE IDENTIFICATION OF RELAPSES IN MULTIPLE SCLEROSIS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
TW201438738A (zh) * 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
WO2010147665A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
EP2648732A4 (en) * 2010-12-07 2014-04-30 Teva Pharma USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS
SG10201606204TA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta
TW201347762A (zh) * 2012-05-02 2013-12-01 Teva Pharma 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
CN105263325A (zh) * 2012-10-12 2016-01-20 梯瓦制药工业有限公司 用于降低多发性硬化症中丘脑损伤的拉喹莫德
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Also Published As

Publication number Publication date
UY35328A (es) 2014-09-30
EP2956137A1 (en) 2015-12-23
BR112015019564A2 (pt) 2017-07-18
SG11201505818WA (en) 2015-08-28
CL2015002181A1 (es) 2016-06-03
IL240014A0 (en) 2015-09-24
MX2015010296A (es) 2016-05-05
CN105163737A (zh) 2015-12-16
US20140235670A1 (en) 2014-08-21
EP2956137A4 (en) 2016-08-03
EA201591507A1 (ru) 2015-12-30
WO2014127139A1 (en) 2014-08-21
JP2016510343A (ja) 2016-04-07
AU2014216199A1 (en) 2015-09-03
TW201442709A (zh) 2014-11-16
HK1218254A1 (zh) 2017-02-10
CA2900503A1 (en) 2014-08-21
KR20150119227A (ko) 2015-10-23
PE20151526A1 (es) 2015-11-20
US20180064702A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
HK1218251A1 (zh) 用拉喹莫德治疗多发性硬化症
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
EA033374B9 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
HK1199820A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
HK1205941A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
WO2013024282A3 (en) Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
PH12012501740A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
WO2016134257A8 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
WO2013038200A3 (en) Neurodevelopmental disorders
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
PL2686005T3 (pl) Kompozycje do podawania miejscowego zawierające diaminooksydazę do leczenia lub zapobiegania chorobom związanym z wysokimi poziomami histaminy, które obejmują nasilenie bólu
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
MX2016001179A (es) Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
PH12020500472A1 (en) Autotaxin inhibitor compounds
HK1227691A1 (zh) 利用拉喹莫德和特立氟胺的组合来治疗多发性硬化症
AR094809A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders